A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects with Asthma

Trial Identifier: 207236
Sponsor: GlaxoSmithKline
Collaborator:
York Bioanalytical Solutions Limited
BI Medical.Inc
SRL Mediserch.Inc
Parexel International Japan
Q2 Solutions LLC
Start Date: June 2017
Primary Completion Date: June 2019
Study Completion Date: June 2019
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Gifu, Japan, 509-6134
Japan Gunma, Japan, 373-0807
Japan Gunma, Japan, 372-0831
Japan Hiroshima, Japan, 732-0052
Japan Kagawa, Japan, 762-8550
Japan Kanagawa, Japan, 236-0004
Japan Kyoto, Japan, 607-8062
Japan Okinawa, Japan, 901-2121
Japan Tokyo, Japan, 169-0073
Japan Tokyo, Japan, 157-0066
Japan Tokyo, Japan, 103-0027
Japan Tokyo, Japan, 134-0083
Japan Toyama, Japan, 937-0042